Trials / Terminated
TerminatedNCT00483041
A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528
A Phase2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528, A Humanized Anti-Interleukin-9 Monoclonal Antibody, on Allergen-Induced Interleukin-9 Levels in Bronchoalveolar Lavage Fluid in Adults With Atopic Asthma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effect of MEDI-528 in adults with atopic asthma.
Detailed description
To evaluate the effect of MEDI-528 on the change in biologically active IL-9 levels in BAL fluid following segmental allergen challenge in adults with atopic asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | PLACEBO | Placebo administered as a single intravenous infusion |
| BIOLOGICAL | MEDI528 9 mg/kg | MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-10-01
- Completion
- 2009-06-01
- First posted
- 2007-06-06
- Last updated
- 2014-03-07
- Results posted
- 2014-03-07
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00483041. Inclusion in this directory is not an endorsement.